Doctors need to be better educated about the significant …
Many doctors recommend a more complete test — colonoscopy — but…
Advertisement
Cos. work on 'biosimilar' cancer drugs
Injectable drugs may be less expensive
Updated: Monday, 19 Dec 2011, 4:53 PM EST
Published : Monday, 19 Dec 2011, 4:53 PM EST
THOUSAND OAKS, Calif. (AP) - The world's biggest biotech firm and a leading generic drugmaker are teaming up to produce "biosimilar" versions of several biologic medicines for cancer.
Amgen Inc., a maker of biologic drugs for cancer, kidney disease and rheumatoid arthritis, says it's partnering with Watson Pharmaceuticals Inc., which makes both generic medicines and branded drugs for women's health and for urologic conditions.
Together, they plan to develop and then sell biosimilars, or generic versions of biologic drugs, under a new joint Amgen/Watson brand. They will not develop biosimilar versions of Amgen's brand-name medicines.
Biologic drugs are complex, injected drugs "manufactured" in living cells, and are very expensive. Biosimilar versions are expected to be a bit cheaper.
Ground rules for posting comments: No profanity or personal attacks. No racially charged comments. If it's not something you would say to someone's face, it's most likely inappropriate. Please comment on the subject of the story itself. If you do not follow these rules, we will remove your post. Repeat offenders will be banned from making future comments. Keep it civil, folks! WANE is not responsible for the content posted in this comment section.
Email This
Print This
View Story on a Single PageAdvertisement
Advertisement
